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to severe acne vulgaris: Phase 2
randomized double-blind, vehicle-
controlled study resultsFig 1. Mean percentage change in inflammatory lesion
count from baseline at each study visit. At baseline, the
mean (SD) number of inflammatory lesions was 33.5 (8.3)
in the FMX-101 4% group (n ¼ 47), 36.5 (9.3) in the
FMX-101 1% group (n ¼ 46), and 33.6 (8.2) in the vehicle
group (n ¼ 46). Modified intent-to-treat analysis. Kruskal-
Wallis test. Last-observation-carried-forward method was
used for all missing observations. *P# .01, yP# .05, FMX-
101 4% or 1% vs vehicle.
Fig 2. Percentage of subjects with Investigator Global
Assessment (IGA) of ‘‘clear’’ or ‘‘almost clear’’ (IGA scores
\2) at each study visit. At baseline, the mean (SD) IGA
score was 3.3 (0.4) in the FMX-101 4% group (n ¼ 47), 3.4
(0.4) in the FMX-101 1% group (n¼ 46), and 3.4 (0.4) in the
vehicle group (n ¼ 46), indicating moderate-to-severe AV.
Modified intent-to-treat analysis. IGA proportions were
compared using Chi-square test. *P # .01, yP # .05,
FMX-101 4% vs vehicle. IGA: 0 ¼ clear, 1 ¼ almost clear,
2 ¼ mild, 3 ¼ moderate, 4 ¼ severe.To the Editor: Acne vulgaris (AV) is a chronic
inflammatory skin disease that affects 80% to 90% of
persons by the age of 21.1 Oral antibiotics, such as
tetracycline, doxycycline, andminocycline, havebeen
a mainstay of treatment for moderate-to-severe AV;
however, their systemic side effects (including un-
common but severe minocycline-induced autoim-
mune reactions such as drug-induced lupus) warrant
the need for alternative treatments.1-3 FMX-101, a new
topical foam formulation of minocycline, was evalu-
ated in a Phase 2, prospective, multicenter, random-
ized, double-blind, dose-finding study conducted in
Tel-Aviv and Netanya, Israel.
The objective of the study was to evaluate
the safety, tolerability, and efficacy of 2 doses of
FMX-101 (1% and 4%) versus vehicle in subjects with
moderate-to-severe AV. Changes in lesion count at
week 12 from baseline and Investigator Global
Assessment (IGA) scores at week 12 were the
co-primary endpoints. Of the 150 subjects screened
and randomized (1:1:1) to FMX-101 4%, FMX-101 1%,
or vehicle, 139 subjects (mean age, 16.5 years [range,
12.3-25]; 48% males) were dispensed study medica-
tions, attended at least one post-baseline visit, and
were included in the modified intent-to-treat analysis.
Subjects applied a small amount of foam (appro-
ximately 0.5 g) to the face once daily for 12 weeks
and returned for 4 post-baseline visits at weeks 3, 6, 9
and 12, and had follow-up visit at 4 weeks after
treatment. Demographic and baseline characteristics
were similar across treatment groups.
Treatment with FMX-101 4% led to a greater mean
percentage reduction from baseline in lesion count
versus vehicle at 12 weeks for both inflammatory
(71.7% vs50.6%;P¼.0001) and noninflammatory
lesions (72.7% vs 56.5%; P ¼ .0197). The signifi-
cant reduction in inflammatory lesions was observed
as early as week 3 and persisted until the study end
(Fig 1). With FMX-101 1%, significant reduction
versus vehicle at week 12 occurred only for inflam-
matory lesions (66.6% vs 50.6%; P ¼ .0072).ª 2015 by the American Academy of Dermatology, Inc. Published by
Elsevier, Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).IGA score was significantly lower for FMX-101 4%
versus vehicle from as early as week 6 (2 vs 2.5;
P¼.01) and persisted until week 12 (1.7 vs 2.4;
P ¼ .0001). Additionally, significantly more patients
treated with FMX-101 4% versus vehicle achieved an
Table I. Retinoid prescription percentages by
specialty, 2012-2014
Total Retinoids Percentage
Patients with acne, total 87,970 48,139 54.7%
Patients with acne seen by
dermatologist
74,371 43,729 58.8%
Patients with acne seen by
nondermatologist
13,599 4410 32.4%
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criterion: IGA score\2) from week 9 until the study
end (week 12: 53.2% vs 19.6%; P¼ .001) (Fig 2). More
subjects treated with FMX-101 4% versus vehicle also
had an IGA improvement of $2 grades at week 12
(36.2% vs 15.2%; P ¼ .021). There was no significant
difference in IGA improvement for FMX-101 1%
versus vehicle.
Treatmentwith FMX-101waswell tolerated and safe,
with no drug-related systemic side effects or serious
adverse events. Five reported adverse events were
transient, mild in severity, and considered unrelated to
the study medication. All adverse events resolved
spontaneously by study end, except for a case of
laryngitis, which was treated with medication. There
wereno significant differences in tolerability parameters
between the FMX-101 and vehicle groups.
Overall, these data suggest that FMX-101 may be
an effective and well-tolerated treatment for
moderate-to-severe AV. FMX-101 4% is the appro-
priate dose for further evaluation in phase 3 trials.
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http://dx.doi.org/10.1016/j.jaad.2015.09.065Use of topical retinoids by dermatologists
and non-dermatologists in the
management of acne vulgarisTo the Editor: Acne vulgaris, a chronic inflammatory
disease of the pilosebaceous unit, is the most com-
mon dermatologic disorder in the United States.1
Recently, both the American Acne and Rosacea
Society, endorsed by the American Academy of
Pediatrics, and the Global Alliance to Improve
Outcomes in Acne published their evidence-based
acne management guidelines recommending that
topical retinoids be used as first-line and mainte-
nance therapy for all types of acne.2,3 The purpose of
this study is to determine how frequently acne
patients are prescribed a retinoid medication by
dermatologists and nondermatologist physicians.
Data were obtained from the Humana database, a
large dataset for claims and reimbursed costs, en-
compassing 18,162,539 patients covered between
2007 and the present. We searched by International
Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) code 706.1 for patients in
the United States with a primary diagnosis code of
acne vulgaris between 2012 and 2014. Within this
group, we identified patients that were prescribed a
retinoid and further separated the data by patients
who were seen by dermatologists or nondermatol-
ogists for the primary diagnosis visit. Further break-
down by gender and age was done. The percentages
of retinoid prescriptions between the 2 groups were
determined and compared. Since registration in the
iPLEDGE Program is not limited to dermatologists,
oral isotretinoin was also included in the study.
Topical retinoids included in the study were
tretinoin, adapalene, and tazarotene, as well as the
brand names associated with them. This study was
declared exempt by the Wake Forest School of
Medicine Institutional Review Board.
From 2012 to 2014, 54.7% of acne patients seen by
all physicians in the database were prescribed a
retinoid. Dermatologists saw 84.5% of all acne
patients, for which 58.8% were prescribed a retinoid.
Nondermatologists saw 15.5% of acne patients, for
which 32.4% were prescribed a retinoid (Table I).
